Evommune licenses Hinova's VAV1 molecular glue degrader outside Greater China
Company / institutional announcement · Evommune and Hinova / Business Wire
Source published: · Event / reporting date: 2026-11-05
Site published: 2026-11-07 · Updated: 2026-11-07
This source is linked automatically. Choose a question to get started.
What changed
Evommune licensed EVO570, formerly HC118, from Hinova for development and commercialization outside Greater China. Upfront consideration totals $30 million: $20 million cash and $10 million in pre-funded warrants. Additional development, regulatory, and commercial milestones could reach approximately $1.1 billion, plus royalties. Phase 1 was expected to begin shortly; the announcement does not establish human efficacy.
Why it may matter
Analysis: The agreement signals partnering interest in immune-cell-directed degradation, but contingent milestones should not be treated as realized revenue or validated therapeutic value.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Edited by the Biotech Assistant content team and reviewed by an authorized publisher. Editorial standards and corrections